- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04620642
Lyon Registry of Stroke Treated by Thrombolysis or Thrombectomy (RELATE)
November 3, 2020 updated by: Hospices Civils de Lyon
This observational study as an objective of characterizing the population of patients treated within the neurovascular unit of the Pierre Wertheimer hospital (Hospices Civils de Lyon) in order to determine their phenotype (age, sex, risk factors, etc.) and its evolution over time.
It also aims to assess the management of ischemic stroke (IS) in the neurovascular unit of Pierre Wertheimer Hospital.
We will assess in particular the pre-hospital and hospital care times, the type of medical care (thrombolysis and / or thrombectomy) as well as the efficiency of this care (effective recanalization, outcome of patient, etc.).
Study Overview
Detailed Description
All patient who has had an IS with an indication of thrombolysis and / or thrombectomy, hospitalized in the neurovascular unit of Pierre Wertheimer Hospital (HCL) since January 2013 and until December 2030 will be contacted for this study
Study Type
Observational
Enrollment (Anticipated)
4500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tae Hee CHO, MD
- Phone Number: 0033 4 72 35 78 07
- Email: tae-hee.cho@chu-lyon.fr
Study Contact Backup
- Name: MArielle BUISSON
- Phone Number: 0033 4 72 35 71 70
- Email: marielle.buisson01@chu-lyon.fr
Study Locations
-
-
-
Lyon, France
- Recruiting
- Hôpital Pierre Wertheimer, GHE, HCL
-
Contact:
- Pr Tae-Hee CHO CHO, MD
- Phone Number: 0033 4 72 35 78 07
- Email: tae-hee.cho@chu-lyon.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients over 18 years old, hospitalized in the neurovascular unit of the Pierre Wertheimer Neurological Hospital (Hospices Civils de Lyon), for an ischemic stroke treated by thrombolysis and / or mechanical thrombectomy and not opposed to this research.
Description
Inclusion Criteria:
- - Patients over 18 years old,
- Hospitalization in the neurovascular unit of the Pierre Wertheimer Neurological Hospital (Hospices Civils de Lyon),
- Ischemic stroke treated by thrombolysis and / or mechanical thrombectomy.
Exclusion Criteria:
- - Opposition to this research.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Registry group
Patients over 18 years old, hospitalized in the neurovascular unit of the Pierre Wertheimer Neurological Hospital (Hospices Civils de Lyon), for an ischemic stroke treated by thrombolysis and / or mechanical thrombectomy and not opposed to this research
|
No specific intervention.
Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phenotype of the population
Time Frame: 3 months
|
Characterization the population of patients with stroke treated by thrombolysis and / or thrombectomy in the neurovascular unit of the Pierre Wertheimer Hospital, Hospices Civils de Lyon : age, sex, risk factors, becoming, etc.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2020
Primary Completion (Anticipated)
March 1, 2031
Study Completion (Anticipated)
March 1, 2031
Study Registration Dates
First Submitted
November 3, 2020
First Submitted That Met QC Criteria
November 3, 2020
First Posted (Actual)
November 9, 2020
Study Record Updates
Last Update Posted (Actual)
November 9, 2020
Last Update Submitted That Met QC Criteria
November 3, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL20_0924
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Registry
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingAchondroplasia | HypochondroplasiaItaly
-
Emory UniversityRecruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Recruiting
-
University of UlmRecruiting
-
Swiss Hemophilia NetworkRecruiting
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ)TerminatedProstatic NeoplasmsUnited States
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ)CompletedHead and Neck NeoplasmsUnited States
-
Clinica Universidad de Navarra, Universidad de...Recruiting
-
Newcastle-upon-Tyne Hospitals NHS TrustRecruitingBethlem Myopathy | Ullrich Congenital Muscular Dystrophy 1, Digenic, Col6A1/Col6A2 | Ullrich Congenital Muscular Dystrophy 1, Autosomal Recessive | Ullrich Congenital Muscular Dystrophy 1, Autosomal Dominant | Bethlem Myopathy 1, Autosomal Recessive | UCMD | BTHLM1United Kingdom
-
Newcastle UniversityLudwig-Maximilians - University of Munich; LGMD2i Research Fund; CureLGMD2iRecruitingLimb Girdle Muscular Dystrophy | Congenital Muscular Dystrophy | LGMDR9 | LGMD2I | Walker-Warburg Syndrome | Muscle-Eye-Brain Disease | FKRP Gene MutationUnited Kingdom